Tempest Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Brisbane, CA
TPST chart
What traders are saying about $TPST
Latest postsTempest Therapeutics, Inc. news
- Top 5 More Healthcare Pre-Market Gainers on Tuesday: Tempest Therapeutics (NASDAQ:TPST) +12.06%, PMV Pharmaceuticals (NASDAQ:PMVP) +11.27%, Iambic Therapeutics (NASDAQ:IAM) +10.69%, Autonomix Medical (NASDAQ:AMIX) +10.00%, Autol
Kalkine ·
- Top 5 Pre-Market Gainers Priced Below USD 1.00 on Tuesday: Co-Diagnostics (NASDAQ:CODX) +29.47%, Skye Bioscience, Inc. (NASDAQ:SKYE) +15.93%, Tempest Therapeutics (NASDAQ:TPST) +12.06%, IceCure Medical (NASDAQ:ICCM) +11.87%, Inno
Kalkine ·
- Why Has Tempest Therapeutics (NASDAQ:TPST) Lifted 12.06% in Pre-Market Trade on Tuesday?
Kalkine ·
- TPST: All four proposals, including director elections and equity issuance approvals, passed
TradingView ·
- Tempest Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
TipRanks ·
- Tempest Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
TradingView ·
- 30 business days below $1 trigger a Nasdaq deadline for Tempest Therapeutics (Nasdaq: TPST).
Stock Titan ·
- TPST Q3'26 Earnings: revenue estimate is 0 USD
TradingView ·
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Yahoo Finance ·
- Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Yahoo Finance ·
- Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Yahoo Finance ·
- Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Yahoo Finance ·
Tempest Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M |
| Diluted EPS | $-6.33 | $-19.50 | $-1.91 | $-3.09 |
| Total assets (year end) | $16.9M | $41.5M | $51.6M | $46.1M |
| Cash and equivalents (year end) | $7.7M | $30.3M | $39.2M | $31.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- DEF 14ADEFINITIVE PROXY STATEMENT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-K8-K
- 8-K8-K
- 8-K8-K
- 8-K8-K
- S-1S-1
- 8-K8-K
About Tempest Therapeutics, Inc.
- Ticker
- TPST (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Brisbane, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc., OvaScience, Inc.
Frequently asked questions
What exchange is Tempest Therapeutics, Inc. listed on?
Tempest Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TPST.
What industry is Tempest Therapeutics, Inc. in?
Tempest Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Tempest Therapeutics, Inc. headquartered?
Tempest Therapeutics, Inc.'s business address on file with the SEC is in Brisbane, CA.
When does Tempest Therapeutics, Inc.'s fiscal year end?
Tempest Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Tempest Therapeutics, Inc. report?
Tempest Therapeutics, Inc. reported $295,000 in revenue for calendar year 2017, according to its SEC filings.